A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer

Wang, An-Jin; Gao, Yang; Shi, Yuying; Dai, Mengyuan; Cai, Hongwei

doi:10.3389/fphar.2022.1093666

Cited by 7 publications

(3 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The immune microenvironment is an essential component of all tumors, playing a key role in tumor development. 28 In addition, the ability to escape immune destruction has been identified as one of the hallmarks of cancer. 29 Immune-associated therapy is a new type of treatment strategy LGG, lower-grade glioma; SKCM, skin cutaneous melanoma; UCEC, uterine corpus endometrial carcinoma; PAAD, pancreatic adenocarcinoma; TGCT, testicular germ cell tumor; BRCA, invasive breast carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; STAD, stomach adenocarcinoma; THYM, thymoma; BLCA, bladder urothelial carcinoma; CESC, cervical squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; PRAD, prostate adenocarcinoma; THCA, thyroid carcinoma; UVM, uveal melanoma.…”

Section: Discussionmentioning

confidence: 99%

Integrated bioinformatic analysis of HNF1A in human cancers

Zhang

Huang

2021

J Int Med Res

View full text Add to dashboard Cite

Objectives Cancer is a threat to human health, and many molecules are involved in the transformation of malignant cells. Hepatocyte nuclear factor 1A (HNF1A) is an important transcription factor that regulates multiple biological processes. Our research focused on elucidating the expression and function of HNF1A in cancer through bioinformatic analysis. Methods UALCAN, Kaplan–Meier plotter, COSMIC, Tumor IMmune Estimation Resource, and Cancer Regulome were used to obtain relevant data for HNF1A. Results HNF1A was abnormally expressed in multiple cancers, and its expression was associated with differences in overall survival in patients with cancer. HNF1A mutations widely exist in tumors and interact with different genes involved in various processes. Additionally, we found that HNF1A was associated with the infiltration of immune cells, and it affected the prognostic value of these cells in some cancers. Conclusions HNF1A plays a crucial role in cancer, and it may represent a biomarker and target for future cancer immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Integrated bioinformatic analysis of HNF1A in human cancers

Zhang

Huang

2021

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…Antitumor therapies depend on the type and stage of the disease. As noted above, current options are surgery, radiation therapy and/or drug treatments [5]. The latter is based on chemotherapy, immunotherapy and targeted therapy [12].…”

Section: Current Chemotherapy Context (Side Effects Resistance and Co...mentioning

confidence: 99%

“…Conventional cancer treatment involve surgery to remove the tumor and followed by radiation therapy when the tumor is located [4]. After metastatic dissemination, cancer chemotherapy, which aims to inhibit the proliferation of tumor cells and induce cancer cell death, is an applicable treatment for many cancers [5]. However, chemotherapy produces various important side effects and can frequently be followed by a multidrug resistance (MDR).…”

Section: Introductionmentioning

confidence: 99%

In vitro activities and mechanisms of action of anti-cancer molecules from African medicinal plants: a systematic review

Adico

2024

Am J Cancer Res

View full text Add to dashboard Cite

Cancer is one of the leading causes of death worldwide. In recent years, African countries have been faced with a rapid increase in morbidity and mortality due to this pathology. Management is often complicated by the high treatment costs, side effects and the increasing occurrence of resistance to treatments. The identification of new active ingredients extracted from endemic medicinal plants is definitively an interesting approach for the implementation of new therapeutic strategies: their extraction is often lower cost; their identification is based on an ethnobotanical history and a tradipratic approach; their use by low-income populations is simpler; this can help in the development of new synthetic molecules that are more active, more effective and with fewer side effects. The objective of this review is to document the molecules derived from African medicinal plants whose in vitro anti-cancer activities and the mechanisms of molecular actions have been identified. From the scientific databases Science Direct, PubMed and Google Scholar, we searched for publications on compounds isolated from African medicinal plants and having activity on cancer cells in culture. The data were analyzed in particular with regard to the cytotoxicity of the compounds and their mode of action. A total of 90 compounds of these African medicinal plants were selected. They come from nine chemical groups: alkaloids, flavonoids, polyphenols, quinones, saponins, steroids, terpenoids, xanthones and organic sulfides. These compounds have been associated with several cellular effects: i) Cytotoxicity, including caspase activation, alteration of mitochondrial membrane potential, and/or induction of reactive oxygen species (ROS); ii) Anti-angiogenesis; iii) Anti-metastatic properties. This review points out that the cited African plants are rich in active ingredients with anticancer properties. It also stresses that screening of these anti-tumor active ingredients should be continued at the continental scale. Altogether, this work provides a rational basis for the selection of phytochemical compounds for use in clinical trials.

show abstract